KDM6A regulates immune response genes in multiple myeloma

2.

Calasanz

MJ

,

Cigudosa

JC

,

Odero

MD

, et al.

Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations

.

Genes Chromosomes Cancer

.

1997

;

18

(

2

):

84

-

93

.

3.

Dewald

GW

,

Kyle

RA

,

Hicks

GA

,

Greipp

PR

.

The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis

.

Blood

.

1985

;

66

(

2

):

380

-

390

.

4.

Sawyer

JR

,

Waldron

JA

,

Jagannath

S

,

Barlogie

B

.

Cytogenetic findings in 200 patients with multiple myeloma

.

Cancer Genet Cytogenet

.

1995

;

82

(

1

):

41

-

49

.

5.

Bergsagel

PL

,

Kuehl

WM

,

Zhan

F

,

Sawyer

J

,

Barlogie

B

,

Shaughnessy

J

.

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

.

Blood

.

2005

;

106

(

1

):

296

-

303

.

6.

Carrasco

DR

,

Tonon

G

,

Huang

Y

, et al.

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients

.

Cancer Cell

.

2006

;

9

(

4

):

313

-

325

.

7.

Issaeva

I

,

Zonis

Y

,

Rozovskaia

T

, et al.

Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth

.

Mol Cell Biol

.

2007

;

27

(

5

):

1889

-

1903

.

8.

Cerami

E

,

Gao

J

,

Dogrusoz

U

, et al.

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data: figure 1

.

Cancer Discov

.

2012

;

2

(

5

):

401

-

404

.

9.

Li

S

,

Lim

HH

,

Woo

KS

,

Kim

SH

,

Han

JY

.

A retrospective analysis of cytogenetic alterations in patients with newly diagnosed multiple myeloma: a single center study in Korea

.

Blood Res

.

2016

;

51

(

2

):

122

-

126

.

10.

Sticca

T

,

Caberg

JH

,

Wenric

S

, et al.

Genomic studies of multiple myeloma reveal an association between X chromosome alterations and genomic profile complexity

.

Genes Chromosomes Cancer

.

2017

;

56

(

1

):

18

-

27

.

11.

Nilsson

T

,

Höglund

M

,

Lenhoff

S

, et al.

A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences

.

Br J Haematol

.

2003

;

120

(

6

):

960

-

969

.

12.

Pawlyn

C

,

Kaiser

MF

,

Heuck

C

, et al.

The spectrum and clinical impact of epigenetic modifier mutations in myeloma

.

Clin Cancer Res

.

2016

;

22

(

23

):

5783

-

5794

.

13.

Ezponda

T

,

Dupéré-Richer

D

,

Will

CM

, et al.

UTX/KDM6A loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition

.

Cell Rep

.

2017

;

21

(

3

):

628

-

640

.

14.

Blatch

GL

,

Lässle

M

.

The tetratricopeptide repeat: a structural motif mediating protein-protein interactions

.

Bioessays

.

1999

;

21

(

11

):

932

-

939

.

15.

Wang

L

,

Shilatifard

A

.

UTX mutations in human cancer

.

Cancer Cell

.

2019

;

35

(

2

):

168

-

176

.

16.

Pawlyn

C

,

Bright

MD

,

Buros

AF

, et al.

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

.

Blood Cancer J

.

2017

;

7

(

3

):

e549

.

17.

Herviou

L

,

Kassambara

A

,

Boireau

S

, et al.

Targeting EZH2 in multiple myeloma could be promising for a subgroup of MM patients in combination with IMiDs

.

Blood

.

2016

;

128

(

22

):

311

.

18.

Ordoñez

R

,

Kulis

M

,

Russiñol

N

, et al.

Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

.

Genome Res

.

2020

;

30

(

9

):

1217

-

1227

.

19.

Shpargel

KB

,

Starmer

J

,

Wang

C

,

Ge

K

,

Magnuson

T

.

UTX-guided neural crest function underlies craniofacial features of Kabuki syndrome

.

Proc Natl Acad Sci U S A

.

2017

;

114

(

43

):

E9046

-

E9055

.

20.

Shi

B

,

Li

W

,

Song

Y

, et al.

UTX condensation underlies its tumour-suppressive activity

.

Nature

.

2021

;

597

(

7878

):

726

-

731

.

21.

Lee

S

,

Lee

JW

,

Lee

SK

.

UTX, a histone H3-lysine 27 demethylase, acts as a critical switch to activate the cardiac developmental program

.

Dev Cell

.

2012

;

22

(

1

):

25

-

37

.

22.

Hardin

J

,

MacLeod

S

,

Grigorieva

I

, et al.

Interleukin-6 prevents dexamethasone-induced myeloma cell death

.

Blood

.

1994

;

84

(

9

):

3063

-

3070

.

23.

Schmidl

C

,

Rendeiro

AF

,

Sheffield

NC

,

Bock

C

.

ChIPmentation: fast, robust, low-input ChIP-seq for histones and transcription factors

.

Nat Methods

.

2015

;

12

(

10

):

963

-

965

.

24.

Allen

K

,

Yellapantula

V

,

Zhao

Q

, et al.

Abstract 5209: characterization of an isogenic model system for KDM6A/UTX loss in multiple myeloma

.

Cancer Res

.

2013

;

73

(

suppl 8

):

5209

.

25.

McLean

CY

,

Bristor

D

,

Hiller

M

, et al.

GREAT improves functional interpretation of cis-regulatory regions

.

Nat Biotechnol

.

2010

;

28

(

5

):

495

-

501

.

26.

Ge

SX

,

Jung

D

,

Yao

R

.

ShinyGO: a graphical gene-set enrichment tool for animals and plants

.

Bioinformatics

.

2020

;

36

(

8

):

2628

-

2629

.

27.

Zheng

R

,

Wan

C

,

Mei

S

, et al.

Cistrome data browser: expanded datasets and new tools for gene regulatory analysis

.

Nucleic Acids Res

.

2019

;

47

(

D1

):

D729

-

D735

.

28.

Heinz

S

,

Benner

C

,

Spann

N

, et al.

Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities

.

Mol Cell

.

2010

;

38

(

4

):

576

-

589

.

29.

Hong

S

,

Cho

YW

,

Yu

LR

,

Yu

H

,

Veenstra

TD

,

Ge

K

.

Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases

.

Proc Natl Acad Sci U S A

.

2007

;

104

(

47

):

18439

-

18444

.

30.

Lee

MG

,

Villa

R

,

Trojer

P

, et al.

Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination

.

Science

.

2007

;

318

(

5849

):

447

-

450

.

31.

Ghandi

M

,

Huang

FW

,

Jané-Valbuena

J

, et al.

Next-generation characterization of the cancer cell line encyclopedia

.

Nature

.

2019

;

569

(

7757

):

503

-

508

.

32.

Hogg

SJ

,

Motorna

O

,

Cluse

LA

, et al.

Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition

.

Mol Cell

.

2021

;

81

(

10

):

2183

-

2200.e13

.

33.

Todaro

GJ

,

Green

H

.

Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines

.

J Cell Biol

.

1963

;

17

(

2

):

299

-

313

.

34.

Welstead

GG

,

Creyghton

MP

,

Bilodeau

S

, et al.

X-linked H3K27me3 demethylase Utx is required for embryonic development in a sex-specific manner

.

Proc Natl Acad Sci U S A

.

2012

;

109

(

32

):

13004

-

13009

.

35.

Walker

BA

,

Boyle

EM

,

Wardell

CP

, et al.

Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma

.

J Clin Oncol

.

2015

;

33

(

33

):

3911

-

3920

.

36.

Li

T

,

Fan

J

,

Wang

B

, et al.

TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells

.

Cancer Res

.

2017

;

77

(

21

):

e108

-

e110

.

37.

Vendramini

E

,

Bomben

R

,

Pozzo

F

, et al.

KRAS and RAS-MAPK pathway deregulation in mature B cell lymphoproliferative disorders

.

Cancers

.

2022

;

14

(

3

):

666

.

38.

Pasca

S

,

Tomuleasa

C

,

Teodorescu

P

, et al.

KRAS/NRAS/BRAF mutations as potential targets in multiple myeloma

.

Front Oncol

.

2019

;

9

:

1137

.

39.

Dhatchinamoorthy

K

,

Colbert

JD

,

Rock

KL

.

Cancer immune evasion through loss of MHC class I antigen presentation

.

Front Immunol

.

2021

;

12

:

636568

.

40.

Axelrod

ML

,

Cook

RS

,

Johnson

DB

,

Balko

JM

.

Biological consequences of MHC-II expression by tumor cells in cancer

.

Clin Cancer Res

.

2019

;

25

(

8

):

2392

-

2402

.

41.

Yang

J

,

Xu

J

,

Wang

W

,

Zhang

B

,

Yu

X

,

Shi

S

.

Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets

.

Signal Transduct Target Ther

.

2023

;

8

(

1

):

210

.

42.

Xia

QD

,

Chen

YB

,

Sun

JX

, et al.

Abstract 2127: TERT C228T and KDM6A alterations are potential predictive biomarkers in non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin instillation

.

Cancer Res

.

2023

;

83

(

suppl 7

):

2127

.

43.

Chen

X

,

Lin

X

,

Pang

G

,

Deng

J

,

Xie

Q

,

Zhang

Z

.

Significance of KDM6A mutation in bladder cancer immune escape

.

BMC Cancer

.

2021

;

21

(

1

):

635

.

44.

Kobatake

K

,

Ikeda

KI

,

Nakata

Y

, et al.

Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization, and causes bladder cancer in cooperation with p53 dysfunction

.

Clin Cancer Res

.

2020

;

26

(

8

):

2065

-

2079

.

45.

Yi

J

,

Shi

X

,

Xuan

Z

,

Wu

J

.

Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma

.

Cancer Lett

.

2021

;

499

:

188

-

200

.

46.

Martin

TD

,

Patel

RS

,

Cook

DR

, et al.

The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation

.

Science

.

2021

;

373

(

6561

):

1327

-

1335

.

47.

Ennishi

D

,

Takata

K

,

Béguelin

W

, et al.

Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition

.

Cancer Discov

.

2019

;

9

(

4

):

546

-

563

.

48.

Burr

ML

,

Sparbier

CE

,

Chan

KL

, et al.

An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer

.

Cancer Cell

.

2019

;

36

(

4

):

385

-

401.e8

.

49.

Bradley

CA

.

PRC2-mediated MHC-I silencing drives immune evasion

.

Nat Rev Cancer

.

2019

;

19

(

12

):

664

.

50.

Wang

SP

,

Tang

Z

,

Chen

CW

, et al.

A UTX-MLL4-p300 transcriptional regulatory network coordinately shapes active enhancer landscapes for eliciting transcription

.

Mol Cell

.

2017

;

67

(

2

):

308

-

321.e6

.

51.

Tran

N

,

Broun

A

,

Ge

K

.

Lysine demethylase KDM6A in differentiation, development, and cancer

.

Mol Cell Biol

.

2020

;

40

(

20

):

e00341-20

.

52.

Zhou

Y

,

Bastian

IN

,

Long

MD

, et al.

Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation

.

Proc Natl Acad Sci U S A

.

2021

;

118

(

8

):

e2025840118

.

53.

Liu

J

,

Xing

L

,

Li

J

, et al.

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma

.

Nat Commun

.

2024

;

15

(

1

):

1367

.

54.

Gozdecka

M

,

Meduri

E

,

Mazan

M

, et al.

UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs

.

Nat Genet

.

2018

;

50

(

6

):

883

-

894

.

55.

Hosogane

M

,

Funayama

R

,

Shirota

M

,

Nakayama

K

.

Lack of transcription triggers H3K27me3 accumulation in the gene body

.

Cell Rep

.

2016

;

16

(

3

):

696

-

706

.

56.

Kriegsman

BA

,

Vangala

P

,

Chen

BJ

, et al.

Frequent loss of IRF2 in cancers leads to immune evasion through decreased MHC class I antigen presentation and increased PD-L1 expression

.

J Immunol

.

2019

;

203

(

7

):

1999

-

2010

.

57.

Hoadley

KA

,

Yau

C

,

Wolf

DM

, et al.

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin

.

Cell

.

2014

;

158

(

4

):

929

-

944

.